SELECT PUBLICATIONS

Coiffier B et al. GELA study comparing CHOP and R-CHOP in elderly patients with DLCL: 3-year median follow-up with an analysis according to comorbidity factors. Presentation. ASCO 2003;Abstract 2395.

Coiffier B et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002;346(4):235-42. Abstract

Feugier P et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: A study by the Groupe d’Etude des Lymphomes de l’Adulte. J Clin Oncol 2005;23(18):4117-26. Abstract

Goy A et al. Bortezomib in patients with relapsed or refractory mantle cell lymphoma (MCL): Preliminary results of the PINNACLE study. Proc ASCO 2005;Abstract 6563.

Hotta T et al. Randomized phase III study of standard CHOP (S-CHOP) versus biweekly CHOP (Bi-CHOP) in aggressive non-hodgkin’s lymphoma (NHL): Japan Clinical Oncology Group study, JCOG9809. Proc ASCO 2003;Abstract 2271.

Kaufmann H et al. Antitumor activity of rituximab plus thalidomide in patients with relapsed/refractory mantle cell lymphoma. Blood 2004;104(8):2269-71. Abstract

Lenz G et al. Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: Results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG). J Clin Oncol 2005;23(9):1984-92. Abstract

O’Connor OA et al. Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin’s lymphoma and mantle cell lymphoma. JClin Oncol 2005;23(4):676-84. Abstract

Pfreundschuh MG et al. Treatment results of CHOP-21, CHOEP-21, MACOP-B and PMitCEBO with and without rituximab in young good-prognosis patients with aggressive lymphomas: Rituximab as an “equalizer” in the MInT (Mabthera International Trial Group) study. Proc ASCO 2005;Abstract 6529.

Pfreundschuh M et al. First analysis of the completed Mabthera International (MInT) Trial in young patients with low-risk diffuse large B-cell lymphoma (DLBCL): Addition of rituximab to a CHOP-like regimen significantly improves outcomes of all patients with the identification of a very favorable subgroup with IPI=0 and no bulky disease. Proc ASH 2004a;Abstract 157.

Pfreundschuh M et al; German High-Grade Non-Hodgkin’s Lymphoma Study Group. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: Results of the NHL-B2 trial of the DSHNHL. Blood 2004b;104(3):634-41. Abstract

Pfreundschuh M et al; German High-Grade Non-Hodgkin’s Lymphoma Study Group. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: Results of the NHL-B1 trial of the DSHNHL. Blood 2004c;104(3):626-33. Abstract

Wilson WH et al. Phase II study of dose-adjusted EPOCH-R in untreated de novo CD20+ diffuse large B-cell lymphoma (DLBCL)-CALGB 50103. Proc ASCO 2005;Abstract 6530.

Wilson WH et al. Dose-adjusted EPOCH-rituximab is highly effective in the GCB and ABC subtypes of untreated diffuse large B-cell lymphoma. Proc ASH 2004;Abstract 159.

Wilson WH et al. The role of rituximab and chemotherapy in aggressive B-cell lymphoma: A preliminary report of dose-adjusted EPOCH-R. Semin Oncol 2002;29(1 Suppl 2):41-7. Abstract